FurazolidoneCAS# 67-45-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 67-45-8 | SDF | Download SDF |
| PubChem ID | 5323714 | Appearance | Powder |
| Formula | C8H7N3O5 | M.Wt | 225 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 10 mg/mL (44.41 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one | ||
| SMILES | C1COC(=O)N1N=CC2=CC=C(O2)[N+](=O)[O-] | ||
| Standard InChIKey | PLHJDBGFXBMTGZ-WEVVVXLNSA-N | ||
| Standard InChI | InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Furazolidone Dilution Calculator
Furazolidone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.4444 mL | 22.2222 mL | 44.4444 mL | 88.8889 mL | 111.1111 mL |
| 5 mM | 0.8889 mL | 4.4444 mL | 8.8889 mL | 17.7778 mL | 22.2222 mL |
| 10 mM | 0.4444 mL | 2.2222 mL | 4.4444 mL | 8.8889 mL | 11.1111 mL |
| 50 mM | 0.0889 mL | 0.4444 mL | 0.8889 mL | 1.7778 mL | 2.2222 mL |
| 100 mM | 0.0444 mL | 0.2222 mL | 0.4444 mL | 0.8889 mL | 1.1111 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Furazolidone is a nitrofuran derivative with antiprotozoal and antibacterial activity, inhibits AML1-ETO transformed cells with IC50 value of 12.7 μM. Target: Antibacterial Furazolidone is a novel therapeutic strategy in AML patients. Furazolidone can Inhibit the bone-marrow transformation mediated by a series of leukemia fusion proteins. Furazolidone significantly inhibits proliferation of AML cell lines. Furazolidone induces apoptosis of the AML leukemic cells treatment with Furazolidone induces differentiation of AML cell lines.
References:
[1]. Jiang X, et al. A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia. PLoS One. 2013 Aug 9;8(8):e72335.
- EGTA
Catalog No.:BCC7491
CAS No.:67-42-5
- Thiamine hydrochloride
Catalog No.:BCN2225
CAS No.:67-03-8
- Tianeptine
Catalog No.:BCC1999
CAS No.:66981-73-5
- Beta-Belladonnine
Catalog No.:BCN1893
CAS No.:6696-63-5
- α-Conotoxin PIA
Catalog No.:BCC5976
CAS No.:669050-68-4
- 1,2-O-Isopropylidene-beta-D-fructopyranose
Catalog No.:BCN1383
CAS No.:66900-93-4
- Talniflumate
Catalog No.:BCC7391
CAS No.:66898-62-2
- H-D-Leu-OBzl.HCl
Catalog No.:BCC2682
CAS No.:66866-69-1
- Halobetasol Propionate
Catalog No.:BCC4664
CAS No.:66852-54-8
- LDN 57444
Catalog No.:BCC2087
CAS No.:668467-91-2
- Linagliptin (BI-1356)
Catalog No.:BCC2110
CAS No.:668270-12-0
- Magnoflorine chloride
Catalog No.:BCN2405
CAS No.:6681-18-1
- 5-Hydroxymethylfurfural
Catalog No.:BCN4226
CAS No.:67-47-0
- Fluocinolone Acetonide
Catalog No.:BCC4906
CAS No.:67-73-2
- Dicyclomine HCl
Catalog No.:BCC3762
CAS No.:67-92-5
- Vitamin D3
Catalog No.:BCN2186
CAS No.:67-97-0
- Gliotoxin
Catalog No.:BCN3894
CAS No.:67-99-2
- Anthriscusin
Catalog No.:BCN3533
CAS No.:67008-16-6
- Methyl isovanillate
Catalog No.:BCN7960
CAS No.:6702-50-7
- 3,4-Dihydroxy-2-methoxyxanthone
Catalog No.:BCN7631
CAS No.:6702-55-2
- Crenolanib (CP-868596)
Catalog No.:BCC3671
CAS No.:670220-88-9
- Ohchinin
Catalog No.:BCN4601
CAS No.:67023-80-7
- Ohchinin acetate
Catalog No.:BCN4220
CAS No.:67023-81-8
- Pepluanin A
Catalog No.:BCN4221
CAS No.:670257-89-3
Hazardous ecotoxicological impact of two commonly used nitrofuran-derived antibacterial drugs: Furazolidone and nitrofurantoin.[Pubmed:30711727]
Chemosphere. 2019 May;222:381-390.
This paper discusses the impact of two nitrofuran-derived drugs, namely Furazolidone and nitrofurantoin on growth of oat and common radish as well as their impact on bacteria Allivibrio fischeri and crustaceans Heterocypris incongruens. Results indicated that both compounds were highly phytotoxic for radish (R. sativus) being simultaneously nearly not harmful for oat (A. sativa). Growing inhibition of shoots, roots, fresh matter and photosynthetic pigments is correlated with growing concentration of drugs in soil. Ecotoxicological impact of both compounds on model luminescence bacteria Aliivibrio fischeri and freshwater crustaceans Heterocypris incongruens as a representative organisms of two different level of food chain, is also reported herein, and the obtained data show significant toxicity against these two organisms. Basing on obtained results, it was concluded that both nitrofuran drugs in case of distribution through environment, by improper utilisation after use or unplanned environmental intoxication with unused drugs may cause serious environmental problems and therefore both should be handled with a reasonable care at any step of their production or utilisation.
Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication.[Pubmed:30386109]
World J Gastroenterol. 2018 Oct 28;24(40):4596-4605.
AIM: To evaluate the outcomes of Furazolidone- and amoxicillin-based quadruple therapy for treatment of Helicobacter pylori (H. pylori) infection and identify predictors of failed eradication. METHODS: Patients with H. pylori infection treated with Furazolidone, amoxicillin, bismuth, and proton pump inhibitor therapy (January 2015 to December 2015) who received the (13)C-urea breath test > 4 wk after treatment were evaluated. Demographic and clinical data including prior H. pylori treatment attempts, medication adherence, alcohol and cigarette consumption during therapy, and treatment-related adverse events were recorded by reviewing medical records and telephone surveys. H. pylori eradication rates for overall and subgroups were evaluated. Multivariate analysis was performed to identify independent predictors of failed H. pylori eradication. RESULTS: Of the 992 patients treated and retested for H. pylori infection, the overall eradication rate was 94.5% [95% confidence interval (CI): 94.1%-95.9%]. H. pylori eradication rate of primary therapy was 95.0% (95%CI: 93.5%-96.5%), while that of rescue therapy was 91.3% (95%CI: 86.8%-95.8%). Among the 859 patients who completed the study protocol, 144 (17%) reported treatment-related adverse events including 24 (3%) leading to premature discontinuation. On multivariate analysis, poor medication adherence [adjusted odds ratio (AOR) = 6.7, 95%CI: 2.8-15.8], two or more previous H. pylori treatments (AOR = 7.4, 95%CI: 2.2-24.9), alcohol consumption during therapy (AOR = 4.4, 95%CI: 1.5-12.3), and possibly smoking during therapy (AOR = 1.9, 95%CI: 0.9-4.3) were associated with failed H. pylori eradication. CONCLUSION: Furazolidone- and amoxicillin-based quadruple therapy for H. pylori infection in an area with a high prevalence of clarithromycin resistance demonstrated high eradication rates as primary and rescue therapies with a favorable safety profile. Patient education targeting abstinence from alcohol during therapy and strict medication adherence may further optimize H. pylori eradication.
